SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
Novel molecular targets of several cytokines are being evaluated by SRI scientists, with the goal of designing a small-molecule drug to block responses involved in many of these inflammatory diseases.
Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.
